(Q84865788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Effect of mycophenolate sodium in scleroderma-related interstitial lung disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

interstitial lung disease

12 February 2020

main subject

1 reference

inferred from title

author name string

Carmen Pilar Simeón-Aznar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Vicent Fonollosa-Plá

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Carles Tolosa-Vilella

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Albert Selva-O'Callaghan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Roser Solans-Laqué

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Miquel Vilardell-Tarrés

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

published in

Clinical Rheumatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1393-1398

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results

12 February 2020

cites work

1 reference

12 December 2020

Spirometric reference values from a Mediterranean population

1 reference

12 December 2020

A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis

1 reference

12 December 2020

Mycophenolate mofetil and its mechanisms of action

1 reference

12 December 2020

Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease

1 reference

12 December 2020

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

12 December 2020

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

1 reference

12 December 2020

Modulation of intra-pulmonary TGF-beta expression by mycophenolate mofetil in lupus prone MRL/lpr mice

1 reference

12 December 2020

Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study

1 reference

12 December 2020

Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.

1 reference

12 December 2020

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

1 reference

12 December 2020

The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis

1 reference

12 December 2020

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

12 December 2020

Pulmonary function tests

1 reference

12 December 2020

Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis

1 reference

12 December 2020

A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis

1 reference

12 December 2020

Predictors of survival in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis

1 reference

12 December 2020

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease

1 reference

12 December 2020

Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.

1 reference

12 December 2020

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

1 reference

12 December 2020

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

1 reference

12 December 2020

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

1 reference

12 December 2020

Mortality in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

1 reference

12 December 2020

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.

1 reference

12 December 2020

Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study

1 reference

12 December 2020

Use of mycophenolate mofetil in autoimmune and renal diseases

1 reference

12 December 2020

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

1 reference

12 December 2020

Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis

1 reference

12 December 2020

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis

1 reference

12 December 2020

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

12 December 2020

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

1 reference

12 December 2020

Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease.

1 reference

12 December 2020

Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation

1 reference

12 December 2020

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

12 December 2020

A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease

1 reference

12 December 2020

Interstitial lung disease in scleroderma

1 reference

12 December 2020

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

1 reference

12 December 2020

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

12 December 2020

Scleroderma lung disease: evolving understanding in light of newer studies

1 reference

12 December 2020

10.1007/S10067-011-1823-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21881859%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference